Atherosclerotic cardiovascular disease (CVD) is worldwide the number one cause of premature mortality, of disability adjusted life years and of increasing health care costs. It affects all countries but the dynamics of the epidemic have been very different between continents and regions. In industrialized countries a peak was reached in the late 1960s and the age-standardized CVD mortality rates have declined thereafter in most of these communities mainly through lifestyle changes and risk factor control.
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In Europe results from surveys among coronary patients and in high-risk subjects have repeatedly shown that the implementation of the European Society of Cardiology (ESC) guidelines on CVD prevention in clinical practice is poorly achieved in real life. [4] [5] [6] [7] [8] [9] The potential for a further reduction of CVD rates is still incompletely utilized in most communities in Europe and North America.
In the meantime CVD has become a major burden in other regions of the world due to demographic changes but also to changes in lifestyle such as increased tobacco smoking, decreased physical activity, less balanced diets, increasing obesity; all this has been associated with more arterial hypertension, dyslipidaemia and dysglycaemia.
Fewer surveys on the CVD risk factor status and on the potential for prevention have been conducted in countries outside the European, the North American and the Australian regions. [10] [11] [12] [13] [14] From what is known it seems that the discrepancies between what guidelines propose and what is achieved in practice are suboptimal and even worse in low-and middle-income countries with less than 10% of patients with CVD on multidrug treatment. 15 In these countries more information is needed on lifestyles, risk factors and CVD burden in order to develop evidence-based prevention strategies. Such local information is also important as educational tools in order to inform health policy makers, health care workers and the public on the potential and the need for CVD prevention.
In this issue of the EJPC results are presented from the International Cholesterol Management Practice Study (ICLPS), 16 a cross-sectional study in 452 centres in 18 countries from Eastern Europe, Asia, Africa, the Middle East and Latin America. The primary objective of this study was to investigate in everyday clinical practice the achievements of low-density lipoprotein cholesterol (LDL-C) targets according to the 2011 ESC/European Atherosclerosis Society guidelines for the management of dyslipidaemias 17 in countries outside Western Europe. In addition physician-estimated total CVD risk was compared with the total CVD risk estimated with the SCORE model. 18 Indeed, in primary prevention of CVD it is of great importance to stratify the population in subgroups of total CVD risk; the rationale for this has to do with cost-effectiveness; limited resources for prevention should be applied as efficiently as possible, meaning that intensive actions should go into those individuals at highest total CVD risk. Estimating the total CVD risk is difficult using clinical judgment only; this has to do with the fact that in most people, atherosclerotic CVD is the product of more than one risk factor. A combination of several modest factors may result in a much higher total CVD risk than a single markedly raised risk factor. These risk factors may interact with each other in a complex synergistic way. Therefore models of risk estimation have been developed.
In the ICLPS over half of the patients at high/veryhigh total CVD risk, according to the SCORE model, was estimated to be at low risk by the clinician and 52% of low risk subjects (according to SCORE) were classified as high risk by the practitioner; this could have resulted in respectively 'under-' and 'over-treatment'.
Multiple risk estimation models exist nowadays but many countries need models that suit best their communities either by re-calibrating existing models or by using more simplified models including risk factors that can all be obtained in the general practitioner's office, as developed by the World Health Organization and the International Society of Hypertension. 19 Regarding the primary objective of the ICLPS the results show that in patients at CVD risk who are on stable lipid lowering drug therapies (LLTs) the achievement of LDL-C goals is suboptimal. The authors conclude that efforts are needed to improve the management of dyslipidaemias in these patients using combination therapy and/or more intensive LLTs.
This may well be true but at the global level much more is needed. The participants in the ICPLS are probably a highly selected subgroup of the populations in which they live; 73% completed secondary or high school; the majority came from urban areas and all were able to afford LLTs. The external validity of the ICPLS may be limited because in most of the participating countries there are great differences between rural and urban areas in educational level and in the access to health practices and in the quality and affordability of care. In the majority of most low-and middleincome countries a large proportion of people at high CVD risk is not detected and certainly not controlled. In these populations there is a need for communitybased programmes in which total CVD risk can be estimated by health care workers who can deliver lifestyle messages and eventually prescribe and monitor effects of effective and safe drugs to control hypertension, diabetes and elevated LDL-C.
Using combinations or more intensive LLTs may be an option in some patients not at goal for LDL-C but one should not forget that multiple risk factors contribute to atherosclerotic CVD. Prevention of CVD is achievable through a reduction of the total CVD risk; if a target cannot be reached with one risk factor total CVD risk can still be reduced by trying harder with others. There is no reason to believe that this principle does not apply to all countries. In the ICPLS the potential for CVD risk reduction beyond the LDL-C level was great: 12.4% were smokers, 34% had elevated blood pressure 140/90 mmHg, 32% were obese, 49% were physically inactive, 46% had the metabolic syndrome (see online Supplementary Material Table 3 of the article). The residual risk in a given patient on LLT should not only be evaluated on the basis of levels of lipid fractions. In the case of severely elevated LDL-C a reduction of >50% may be the best achievable without reaching the target levels set in the guidelines, but in these situations the control of all other major CVD risk factors should receive even more attention.
One should also remember that lipid levels, and particularly the LDL-C level, can be influenced by dietary habits. Susceptibility to the intake of fatty acids is very different between individuals but in some cases the amount of LDL-C reduction by diet compares well with many of the LLTs. 20 Given the cultural diversity of populations and the complexity of behavioural changes, local nutritionists and dieticians should be involved to translate dietary recommendations on nutrients into practical behaviour taking into account local food habits and socio-economic factors.
If LLTs with drugs become inevitable then one should realize that there exists a considerable interindividual variation in the LDL-C reduction at all doses of the most frequently used statins; 21 this may be explained to a certain extent by non-compliance but also through genetic profiles that predispose to achieve larger reductions of atherogenic lipoproteins while others respond poorly. This implies that a 'fire and forget' strategy is not recommended but that, on the contrary, safety and efficacy should be monitored in all patients in whom LLTs are started.
The efficacy and safety of combinations is actually available for statins plus ezetimibe 22 and for statins plus the PCSK9 inhibitors evolocumab 23 and alirocumab 24 but the use of these PCSK9 inhibitors is at this moment hampered by economic constraints. LDL-C targets have been set in all guidelines on CVD prevention based on results from randomized controlled trials. Less is known on how to achieve these goals. The gap between knowledge and implementation is related to different barriers that exist at the level of the patient, the practitioner and the health care system. One of the disadvantages of prevention of chronic non-communicable diseases is that it gives few immediate rewards. The patient has to be pleased with the fact that nothing happens. But to achieve that he has to take on a daily basis multiple drugs for a long period. It is not surprising that the compliance with such regimens is low especially when the patient is not fully informed on why he has to take these medications regularly. Communication with the patient is essential and should be adapted to educational, socioeconomic and ethnic issues. Polypills may promote compliance and therefore improve the goal achievements in a number of patients. 25 At the level of the practitioner a certain degree of inertia may be the reason for not achieving the LDL-C goal. In patients with established CVD one should start from the beginning with high-intensity statin and switch to a combination of ezetimibe with the highest tolerated high-intensity statin if the LDL-C goal is not achieved after some weeks. In primary prevention the choice of the drug and the dosage will depend of the baseline value of LDL-C and of the goal that one wants to achieve; but monitoring, communication and followup remain essential in all patients.
Finally, the health care system, and particularly the health insurance system, plays an important role in the implementation of guidelines, especially in certain socio-economic subgroups of the population. Widespread provision at no or subsidized costs of generic LLTs and of polypills could reduce the gap between what is recommended and what is realized in daily practice to control CVD.
It is clear that the implementation of guidelines on CVD prevention into practice necessitates more than combination therapy or more intense LLTs. Based on known barriers multifaceted interventions are needed. Such programmes have been elaborated for the primary and secondary prevention of CVD. 26, 27 These interventions need to be evaluated using community and clinical audit projects in many settings in different countries of the world.
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